Teaching Health Resilience in a Hospital Setting: A Peer-led Intervention

NCT06843213 | Recruiting DMC

• 2 other identifiers: 8575811R01DA057633
• Study Type: interventional
• Target: 390
• Locations: 1 country
• Sites: 3

Brief Summary

The purpose of the study is to develop an acceptable, feasible, and effective peer-led bundle of health resilience and promotion services to be delivered in the hospital setting, called the THRIVE intervention. The main question it aims to answer is: Will participants receiving the THRIVE intervention have a reduced risk of self-reported non-fatal overdoses OR skin/soft tissue infections compared to participants receiving enhanced usual care? Researchers will compare the THRIVE model to enhanced usual care to see if the THRIVE model helps participants reduce their number of self-reported non-fatal overdoses OR skin/soft tissue infections. Intervention participants will:

• Receive one in-person session from a peer support specialist while in the hospital
• Receive weekly text messages from the peer support specialist for a 12-week period
• Receive monthly, multiple-choice assessments via text message at Month 1, 2, 3, 4, 5, and 6
• Complete a baseline, 3-month, and 6-month assessment with Research Assistants Enhanced usual care participants will:
• Receive a handout with health resilience education and resources in their local area
• Receive monthly, multiple-choice assessments via text message at Month 1, 2, 3, 4, 5, and 6
• Complete a baseline, 3-month, and 6-month assessment with Research Assistants

Conditions

Harm Reduction; Health Promotion; Opioid Use Disorder

Keywords

Opioid Use Disorder; Harm Reduction; Peer Support; Peer Support Specialists

Outcome Measures

Primary Outcomes (1)

• Effectiveness of the THRIVE intervention compared to enhanced usual care (EUC) at lowering the incidence of non-fatal overdoses OR skin and soft tissue infections

  Cumulative incidence of non-fatal overdose OR skin and soft tissue infection

  Baseline to 6 months

Secondary Outcomes (2)

• Effectiveness of the THRIVE intervention compared to EUC at lowering the incidence of non-fatal overdoses

  Baseline to 6 months

• Effectiveness of the THRIVE intervention compared to EUC at lowering the incidence of skin and soft tissue infections

  Baseline to 6 months

Other Outcomes (8)

• Effectiveness of the THRIVE intervention on change in higher risk infection behaviors (characterized by BIRSI score) compared to EUC

  Baseline to 6 months

• Effectiveness of the THRIVE intervention on change in health resilience adoption compared to EUC (a)

  Baseline to 6 months

• Effectiveness of the THRIVE intervention on change in health resilience adoption compared to EUC (b)

  Baseline to 6 months

Study Arms (2)

Peer Intervention

EXPERIMENTAL

Behavioral: Peer Intervention

Enhanced Usual Care

OTHER

Other: Enhanced Usual Care

Interventions

Peer Intervention BEHAVIORAL

Participants will receive one peer-led, in-person session boosted by weekly text messages over a 12-week period.

Peer Intervention

Enhanced Usual Care OTHER

Participants will receive a handout that includes health resilience education and resources in their local area as part of enhanced usual care.

Enhanced Usual Care

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Participants who are: a) admitted to University of Pittsburgh Medical Center (UPMC) Shadyside Hospital, UPMC Presbyterian-Montefiore Hospital, UPMC Mercy Hospital for inpatient or observation status, or b) seen in the Emergency Department setting at UPMC Presbyterian-Montefiore Hospital and UPMC Mercy Hospital.
• Participants must have a current diagnosis of Opioid Use Disorder based on the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) diagnostic criteria.
• Participants must be at least 18 years of age on day of admission.
• Participants must be able to speak and read English.

You may not qualify if:

• Participants diagnosed with dementia and/or cognitive impairments.
• Participants with acute psychiatric complications, such as schizophrenia with acute psychosis, acute mania, or suicidal ideation (which may impact the ability of a participant to consent and actively participate in treatment).
• Participants who are pregnant or lactating at onset of study.
• Participants who cannot read or speak English.

Sponsors & Collaborators

• University of Pennsylvania: lead
• National Institute on Drug Abuse (NIDA): collaborator
• University of Pittsburgh: collaborator

Study Sites (3)

UPMC Mercy Hospital

Pittsburgh, Pennsylvania, 15203, United States

NOT YET RECRUITING

UPMC Presbyterian-Montefiore Hospital

Pittsburgh, Pennsylvania, 15213, United States

RECRUITING

UPMC Shadyside Hospital

Pittsburgh, Pennsylvania, 15232, United States

NOT YET RECRUITING

Related Publications (47)

• Harm Reduction Principles. National Harm Reduction Coalition. Accessed September 9, 2022. https://harmreduction.org/about-us/principles-of-harm-reduction/

  BACKGROUND

• Friedman SR, de Jong W, Rossi D, Touze G, Rockwell R, Des Jarlais DC, Elovich R. Harm reduction theory: users' culture, micro-social indigenous harm reduction, and the self-organization and outside-organizing of users' groups. Int J Drug Policy. 2007 Mar;18(2):107-17. doi: 10.1016/j.drugpo.2006.11.006. Epub 2006 Dec 28.

  PMID: 17689353 BACKGROUND

• Pauly BB, Reist D, Belle-Isle L, Schactman C. Housing and harm reduction: what is the role of harm reduction in addressing homelessness? Int J Drug Policy. 2013 Jul;24(4):284-90. doi: 10.1016/j.drugpo.2013.03.008. Epub 2013 Apr 25.

  PMID: 23623720 BACKGROUND

• Pauly B, Wallace B, Barber K. Turning a blind eye: implementation of harm reduction in a transitional programme setting. Drugs Educ Prev Policy. 2018;25(1):21-30. doi:10.1080/09687637.2017.1337081

  BACKGROUND

• Pauly B. Harm reduction through a social justice lens. Int J Drug Policy. 2008 Feb;19(1):4-10. doi: 10.1016/j.drugpo.2007.11.005. Epub 2008 Jan 15.

  PMID: 18226520 BACKGROUND

• Stein MD, Phillips KT, Herman DS, Keosaian J, Stewart C, Anderson BJ, Weinstein Z, Liebschutz J. Skin-cleaning among hospitalized people who inject drugs: a randomized controlled trial. Addiction. 2021 May;116(5):1122-1130. doi: 10.1111/add.15236. Epub 2020 Sep 21.

  PMID: 32830383 BACKGROUND

• Phillips KT, Stewart C, Anderson BJ, Liebschutz JM, Herman DS, Stein MD. A randomized controlled trial of a brief behavioral intervention to reduce skin and soft tissue infections among people who inject drugs. Drug Alcohol Depend. 2021 Apr 1;221:108646. doi: 10.1016/j.drugalcdep.2021.108646. Epub 2021 Feb 27.

  PMID: 33677353 BACKGROUND

• Moustaqim-Barrette A, Dhillon D, Ng J, Sundvick K, Ali F, Elton-Marshall T, Leece P, Rittenbach K, Ferguson M, Buxton JA. Take-home naloxone programs for suspected opioid overdose in community settings: a scoping umbrella review. BMC Public Health. 2021 Mar 26;21(1):597. doi: 10.1186/s12889-021-10497-2.

  PMID: 33771150 BACKGROUND

• McDonald R, Strang J. Are take-home naloxone programmes effective? Systematic review utilizing application of the Bradford Hill criteria. Addiction. 2016 Jul;111(7):1177-87. doi: 10.1111/add.13326. Epub 2016 Mar 30.

  PMID: 27028542 BACKGROUND

• Krieger MS, Yedinak JL, Buxton JA, Lysyshyn M, Bernstein E, Rich JD, Green TC, Hadland SE, Marshall BDL. High willingness to use rapid fentanyl test strips among young adults who use drugs. Harm Reduct J. 2018 Feb 8;15(1):7. doi: 10.1186/s12954-018-0213-2.

  PMID: 29422052 BACKGROUND

• Sherman SG, Morales KB, Park JN, McKenzie M, Marshall BDL, Green TC. Acceptability of implementing community-based drug checking services for people who use drugs in three United States cities: Baltimore, Boston and Providence. Int J Drug Policy. 2019 Jun;68:46-53. doi: 10.1016/j.drugpo.2019.03.003. Epub 2019 Apr 13.

  PMID: 30991301 BACKGROUND

• Goldman JE, Waye KM, Periera KA, Krieger MS, Yedinak JL, Marshall BDL. Perspectives on rapid fentanyl test strips as a harm reduction practice among young adults who use drugs: a qualitative study. Harm Reduct J. 2019 Jan 8;16(1):3. doi: 10.1186/s12954-018-0276-0.

  PMID: 30621699 BACKGROUND

• Peiper NC, Clarke SD, Vincent LB, Ciccarone D, Kral AH, Zibbell JE. Fentanyl test strips as an opioid overdose prevention strategy: Findings from a syringe services program in the Southeastern United States. Int J Drug Policy. 2019 Jan;63:122-128. doi: 10.1016/j.drugpo.2018.08.007. Epub 2018 Oct 3.

  PMID: 30292493 BACKGROUND

• Hawk M, Coulter RWS, Egan JE, Fisk S, Reuel Friedman M, Tula M, Kinsky S. Harm reduction principles for healthcare settings. Harm Reduct J. 2017 Oct 24;14(1):70. doi: 10.1186/s12954-017-0196-4.

  PMID: 29065896 BACKGROUND

• Chan CA, Canver B, McNeil R, Sue KL. Harm Reduction in Health Care Settings. Med Clin North Am. 2022 Jan;106(1):201-217. doi: 10.1016/j.mcna.2021.09.002.

  PMID: 34823731 BACKGROUND

• Wilson JD, Berk J, Adger H, Feldman L. Identifying Missed Clinical Opportunities in Delivery of Overdose Prevention and Naloxone Prescription to Adolescents Using Opioids. J Adolesc Health. 2018 Aug;63(2):245-248. doi: 10.1016/j.jadohealth.2018.05.011.

  PMID: 30149925 BACKGROUND

• Wilson JD, Spicyn N, Matson P, Alvanzo A, Feldman L. Internal medicine resident knowledge, attitudes, and barriers to naloxone prescription in hospital and clinic settings. Subst Abus. 2016 Jul-Sep;37(3):480-487. doi: 10.1080/08897077.2016.1142921. Epub 2016 Jan 28.

  PMID: 26820604 BACKGROUND

• Deanna Wilson J, Berk J, Matson P, Spicyn N, Alvanzo A, Adger H, Feldman L. A Cross-sectional Survey Using Clinical Vignettes to Examine Overdose Risk Assessment and Willingness to Prescribe Naloxone. J Gen Intern Med. 2019 Apr;34(4):507-509. doi: 10.1007/s11606-018-4733-y. No abstract available.

  PMID: 30406568 BACKGROUND

• Macalino GE, Sachdev DD, Rich JD, Becker C, Tan LJ, Beletsky L, Burris S. A national physician survey on prescribing syringes as an HIV prevention measure. Subst Abuse Treat Prev Policy. 2009 Jun 8;4:13. doi: 10.1186/1747-597X-4-13.

  PMID: 19505336 BACKGROUND

• Stack E, Hildebran C, Leichtling G, Waddell EN, Leahy JM, Martin E, Korthuis PT. Peer Recovery Support Services Across the Continuum: In Community, Hospital, Corrections, and Treatment and Recovery Agency Settings - A Narrative Review. J Addict Med. 2022 Jan-Feb 01;16(1):93-100. doi: 10.1097/ADM.0000000000000810.

  PMID: 33560695 BACKGROUND

• Mercer F, Miler JA, Pauly B, Carver H, Hnizdilova K, Foster R, Parkes T. Peer Support and Overdose Prevention Responses: A Systematic 'State-of-the-Art' Review. Int J Environ Res Public Health. 2021 Nov 17;18(22):12073. doi: 10.3390/ijerph182212073.

  PMID: 34831839 BACKGROUND

• Kennedy MC, Boyd J, Mayer S, Collins A, Kerr T, McNeil R. Peer worker involvement in low-threshold supervised consumption facilities in the context of an overdose epidemic in Vancouver, Canada. Soc Sci Med. 2019 Mar;225:60-68. doi: 10.1016/j.socscimed.2019.02.014. Epub 2019 Feb 10.

  PMID: 30798157 BACKGROUND

• Owczarzak J, Weicker N, Urquhart G, Morris M, Park JN, Sherman SG. "We know the streets:" race, place, and the politics of harm reduction. Health Place. 2020 Jul;64:102376. doi: 10.1016/j.healthplace.2020.102376. Epub 2020 Jul 22.

  PMID: 32838893 BACKGROUND

• Bardwell G, Kerr T, Boyd J, McNeil R. Characterizing peer roles in an overdose crisis: Preferences for peer workers in overdose response programs in emergency shelters. Drug Alcohol Depend. 2018 Sep 1;190:6-8. doi: 10.1016/j.drugalcdep.2018.05.023. Epub 2018 Jun 26.

  PMID: 29960202 BACKGROUND

• Pauly B, Wallace B, Pagan F, Phillips J, Wilson M, Hobbs H, Connolly J. Impact of overdose prevention sites during a public health emergency in Victoria, Canada. PLoS One. 2020 May 21;15(5):e0229208. doi: 10.1371/journal.pone.0229208. eCollection 2020.

  PMID: 32438390 BACKGROUND

• Small W, Wood E, Tobin D, Rikley J, Lapushinsky D, Kerr T. The Injection Support Team: a peer-driven program to address unsafe injecting in a Canadian setting. Subst Use Misuse. 2012 Apr;47(5):491-501. doi: 10.3109/10826084.2012.644107.

  PMID: 22428817 BACKGROUND

• Hayashi K, Wood E, Wiebe L, Qi J, Kerr T. An external evaluation of a peer-run outreach-based syringe exchange in Vancouver, Canada. Int J Drug Policy. 2010 Sep;21(5):418-21. doi: 10.1016/j.drugpo.2010.03.002. Epub 2010 Mar 31.

  PMID: 20359877 BACKGROUND

• Dechman MK. Peer helpers' struggles to care for "others" who inject drugs. Int J Drug Policy. 2015 May;26(5):492-500. doi: 10.1016/j.drugpo.2014.12.010. Epub 2015 Jan 8.

  PMID: 25630481 BACKGROUND

• Marshall C, Perreault M, Archambault L, Milton D. Experiences of peer-trainers in a take-home naloxone program: Results from a qualitative study. Int J Drug Policy. 2017 Mar;41:19-28. doi: 10.1016/j.drugpo.2016.11.015. Epub 2016 Dec 24.

  PMID: 28027483 BACKGROUND

• Callon C, Charles G, Alexander R, Small W, Kerr T. 'On the same level': facilitators' experiences running a drug user-led safer injecting education campaign. Harm Reduct J. 2013 Mar 6;10:4. doi: 10.1186/1477-7517-10-4.

  PMID: 23497293 BACKGROUND

• Colon RM, Deren S, Guarino H, Mino M, Kang SY. Challenges in recruiting and training drug treatment patients as peer outreach workers: a perspective from the field. Subst Use Misuse. 2010 Oct;45(12):1892-908. doi: 10.3109/10826081003684863.

  PMID: 20380554 BACKGROUND

• Newland J, Treloar C. Peer education for people who inject drugs in New South Wales: Advantages, unanticipated benefits and challenges. Drugs Educ Prev Policy. 2013;20(4):304-311. doi:10.3109/09687637.2012.761951

  BACKGROUND

• Hay B, Henderson C, Maltby J, Canales JJ. Influence of Peer-Based Needle Exchange Programs on Mental Health Status in People Who Inject Drugs: A Nationwide New Zealand Study. Front Psychiatry. 2017 Jan 18;7:211. doi: 10.3389/fpsyt.2016.00211. eCollection 2016.

  PMID: 28149282 BACKGROUND

• Cacari-Stone L, Wallerstein N, Garcia AP, Minkler M. The promise of community-based participatory research for health equity: a conceptual model for bridging evidence with policy. Am J Public Health. 2014 Sep;104(9):1615-23. doi: 10.2105/AJPH.2014.301961. Epub 2014 Jul 17.

  PMID: 25033119 BACKGROUND

• Adams SA, Heiney SP, Brandt HM, Wirth MD, Khan S, Johnson H, Davis L, Wineglass CM, Warren-Jones TY, Felder TM, Drayton RF, Davis B, Farr DE, Hebert JR. A comparison of a centralized versus de-centralized recruitment schema in two community-based participatory research studies for cancer prevention. J Community Health. 2015 Apr;40(2):251-9. doi: 10.1007/s10900-014-9924-9.

  PMID: 25086566 BACKGROUND

• Burke JG, Jones J, Yonas M, Guizzetti L, Virata MC, Costlow M, Morton SC, Elizabeth M. PCOR, CER, and CBPR: alphabet soup or complementary fields of health research? Clin Transl Sci. 2013 Dec;6(6):493-6. doi: 10.1111/cts.12064. Epub 2013 May 8.

  PMID: 24330697 BACKGROUND

• Horowitz CR, Brenner BL, Lachapelle S, Amara DA, Arniella G. Effective recruitment of minority populations through community-led strategies. Am J Prev Med. 2009 Dec;37(6 Suppl 1):S195-200. doi: 10.1016/j.amepre.2009.08.006.

  PMID: 19896019 BACKGROUND

• Wilson JD, Altieri Dunn SC, Roy P, Joseph E, Klipp S, Liebschutz J. Inpatient Addiction Medicine Consultation Service Impact on Post-discharge Patient Mortality: a Propensity-Matched Analysis. J Gen Intern Med. 2022 Aug;37(10):2521-2525. doi: 10.1007/s11606-021-07362-8. Epub 2022 Jan 25.

  PMID: 35076857 BACKGROUND

• Ojo SO, Bailey DP, Hewson DJ, Chater AM. Perceived Barriers and Facilitators to Breaking Up Sitting Time among Desk-Based Office Workers: A Qualitative Investigation Using the TDF and COM-B. Int J Environ Res Public Health. 2019 Aug 14;16(16):2903. doi: 10.3390/ijerph16162903.

  PMID: 31416112 BACKGROUND

• McDonagh LK, Saunders JM, Cassell J, Curtis T, Bastaki H, Hartney T, Rait G. Application of the COM-B model to barriers and facilitators to chlamydia testing in general practice for young people and primary care practitioners: a systematic review. Implement Sci. 2018 Oct 22;13(1):130. doi: 10.1186/s13012-018-0821-y.

  PMID: 30348165 BACKGROUND

• Timlin D, McCormack JM, Simpson EE. Using the COM-B model to identify barriers and facilitators towards adoption of a diet associated with cognitive function (MIND diet). Public Health Nutr. 2021 May;24(7):1657-1670. doi: 10.1017/S1368980020001445. Epub 2020 Aug 17.

  PMID: 32799963 BACKGROUND

• Curran GM, Bauer M, Mittman B, Pyne JM, Stetler C. Effectiveness-implementation hybrid designs: combining elements of clinical effectiveness and implementation research to enhance public health impact. Med Care. 2012 Mar;50(3):217-26. doi: 10.1097/MLR.0b013e3182408812.

  PMID: 22310560 BACKGROUND

• Binswanger IA, Kral AH, Bluthenthal RN, Rybold DJ, Edlin BR. High prevalence of abscesses and cellulitis among community-recruited injection drug users in San Francisco. Clin Infect Dis. 2000 Mar;30(3):579-81. doi: 10.1086/313703.

  PMID: 10722447 BACKGROUND

• Fink DS, Lindsay SP, Slymen DJ, Kral AH, Bluthenthal RN. Abscess and self-treatment among injection drug users at four California syringe exchanges and their surrounding communities. Subst Use Misuse. 2013 May;48(7):523-31. doi: 10.3109/10826084.2013.787094. Epub 2013 Apr 12.

  PMID: 23581506 BACKGROUND

• Shrestha S, Stopka TJ, Hughto JMW, Case P, Palacios WR, Reilly B, Green TC. Prevalence and correlates of non-fatal overdose among people who use drugs: findings from rapid assessments in Massachusetts, 2017-2019. Harm Reduct J. 2021 Aug 30;18(1):93. doi: 10.1186/s12954-021-00538-9.

  PMID: 34461922 BACKGROUND

• Stensrud MJ, Hernan MA. Why Test for Proportional Hazards? JAMA. 2020 Apr 14;323(14):1401-1402. doi: 10.1001/jama.2020.1267. No abstract available.

  PMID: 32167523 BACKGROUND

• Bradburn MJ, Clark TG, Love SB, Altman DG. Survival analysis Part III: multivariate data analysis -- choosing a model and assessing its adequacy and fit. Br J Cancer. 2003 Aug 18;89(4):605-11. doi: 10.1038/sj.bjc.6601120. No abstract available.

  PMID: 12915864 BACKGROUND

MeSH Terms

Conditions

Opioid-Related Disorders; Harm Reduction

Condition Hierarchy (Ancestors)

Narcotic-Related Disorders; Substance-Related Disorders; Chemically-Induced Disorders; Mental Disorders; Behavior

Study Officials

• Jacqueline D Wilson, MD

  University of Pennsylvania

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Research Program Coordinator

CONTACT

412-679-9848; thriving@pitt.edu

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 13, 2025
• First Posted: February 24, 2025
• Study Start: February 18, 2025
• Primary Completion (Estimated): April 1, 2028
• Study Completion (Estimated): August 1, 2028
• Last Updated: February 27, 2026

Record last verified: 2026-02

Data Sharing

• IPD Sharing: Will not share

Locations

US (3)